CN107249691A - 用于肺结核治疗的多药疗法 - Google Patents

用于肺结核治疗的多药疗法 Download PDF

Info

Publication number
CN107249691A
CN107249691A CN201580059556.0A CN201580059556A CN107249691A CN 107249691 A CN107249691 A CN 107249691A CN 201580059556 A CN201580059556 A CN 201580059556A CN 107249691 A CN107249691 A CN 107249691A
Authority
CN
China
Prior art keywords
mice
drug
treatment
fsc
regimen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580059556.0A
Other languages
English (en)
Chinese (zh)
Inventor
何志明
丹尼尔·L·克莱门斯
白羽·李·克莱门斯
马库斯·亚伦·霍维茨
奥蕾蒂·玛琳·席尔瓦·维特
希欧多尔·凯
丁显廷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiao Tong University
University of California
Original Assignee
Shanghai Jiao Tong University
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiao Tong University, University of California filed Critical Shanghai Jiao Tong University
Publication of CN107249691A publication Critical patent/CN107249691A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580059556.0A 2014-11-03 2015-11-03 用于肺结核治疗的多药疗法 Pending CN107249691A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462074508P 2014-11-03 2014-11-03
US62/074,508 2014-11-03
US201562217306P 2015-09-11 2015-09-11
US62/217,306 2015-09-11
PCT/US2015/058892 WO2016073524A1 (en) 2014-11-03 2015-11-03 Multi-drug therapies for tuberculosis treatment

Publications (1)

Publication Number Publication Date
CN107249691A true CN107249691A (zh) 2017-10-13

Family

ID=55909721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580059556.0A Pending CN107249691A (zh) 2014-11-03 2015-11-03 用于肺结核治疗的多药疗法

Country Status (5)

Country Link
US (2) US10080749B2 (enExample)
EP (1) EP3215225B1 (enExample)
JP (1) JP2017533220A (enExample)
CN (1) CN107249691A (enExample)
WO (1) WO2016073524A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112089713A (zh) * 2020-09-18 2020-12-18 中国科学院广州生物医药与健康研究院 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016287478B2 (en) 2015-07-02 2021-10-21 Janssen Sciences Ireland Uc Antibacterial compounds
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
US11224596B2 (en) * 2017-03-01 2022-01-18 Janssen Sciences Ireland Unlimited Company PZA and cytochrome bc1 inhibitor combination treatment
WO2018191628A1 (en) * 2017-04-14 2018-10-18 The Regents Of The University Of California Multi-drug therapies for tuberculosis treatment
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
WO2021076058A1 (en) * 2019-10-18 2021-04-22 National University Of Singapore Method for predicting a suitable therapy
WO2021257466A1 (en) * 2020-06-15 2021-12-23 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and method for antibacterial therapy
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020068761A1 (en) * 1999-10-04 2002-06-06 Bernstein Lawrence R. Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
NZ591169A (en) * 2008-09-03 2012-12-21 Pfizer Combination therapy for tuberculosis
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARMAND VAN DEUN等: "Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis", 《AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE》 *
EMILY B. WONG等: "Rising to the challenge: new therapies for tuberculosis", 《TRENDS IN MICROBIOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112089713A (zh) * 2020-09-18 2020-12-18 中国科学院广州生物医药与健康研究院 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物
CN112089713B (zh) * 2020-09-18 2022-02-22 中国科学院广州生物医药与健康研究院 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物

Also Published As

Publication number Publication date
WO2016073524A1 (en) 2016-05-12
JP2017533220A (ja) 2017-11-09
EP3215225A1 (en) 2017-09-13
US20190030026A1 (en) 2019-01-31
EP3215225A4 (en) 2018-05-30
EP3215225B1 (en) 2020-01-08
US10576079B2 (en) 2020-03-03
US20170333427A1 (en) 2017-11-23
US10080749B2 (en) 2018-09-25

Similar Documents

Publication Publication Date Title
CN107249691A (zh) 用于肺结核治疗的多药疗法
JP7221922B2 (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
JP6873110B2 (ja) クロストリジウム属感染を処置するためのハロゲン化サリチルアニリド
KR102834026B1 (ko) 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법
CN105579432A (zh) 治疗感染的化合物和方法
CN101686972A (zh) 治疗用组合物和方法
CN105848656A (zh) 药物组合
US11857540B2 (en) Pemafibrate dosing regimens
CA2768582C (en) Spectinamides as anti-tuberculosis agents
US11672806B2 (en) Methods and compositions for treating mesothelioma and small lung cancer that express midkine
JP6279583B2 (ja) アスペルギルス等の病原微生物による疾患用の医薬組成物
DK2928299T3 (en) TREATMENT OF CHRONIC SKIN INFLAMMATION WITH THE NORKETOTIFY
JP6563998B2 (ja) 治療計画
US20150272941A1 (en) Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
JP7654544B2 (ja) ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
Lee et al. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy
US20230277524A1 (en) Combination therapy for treatment of viral infections
JP2016508957A (ja) カンジダ等の病原微生物による疾患用の医薬組成物
Maincent et al. Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection
JP2020040978A (ja) サルコイドーシスを処置するための１，３−プロパンジスルホン酸またはその薬学的に許容される塩の使用
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
WO2025061104A1 (zh) 一种药物组合及应用
WO2018191628A1 (en) Multi-drug therapies for tuberculosis treatment
EP4122466A1 (en) Entrectinib as antiviral agent
JP2012520864A (ja) 結核の治療のための化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20171013